APA
Fischer T., Stone R. M., Deangelo D. J., Galinsky I., Estey E., Lanza C., Fox E., Ehninger G., Feldman E. J., Schiller G. J., Klimek V. M., Nimer S. D., Gilliland D. G., Dutreix C., Huntsman-Labed A., Virkus J. & Giles F. J. (20101102). Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Chicago
Fischer Thomas, Stone Richard M, Deangelo Daniel J, Galinsky Ilene, Estey Elihu, Lanza Carlo, Fox Edward, Ehninger Gerhard, Feldman Eric J, Schiller Gary J, Klimek Virginia M, Nimer Stephen D, Gilliland D Gary, Dutreix Catherine, Huntsman-Labed Alice, Virkus Jodi and Giles Francis J. 20101102. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Harvard
Fischer T., Stone R. M., Deangelo D. J., Galinsky I., Estey E., Lanza C., Fox E., Ehninger G., Feldman E. J., Schiller G. J., Klimek V. M., Nimer S. D., Gilliland D. G., Dutreix C., Huntsman-Labed A., Virkus J. and Giles F. J. (20101102). Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
MLA
Fischer Thomas, Stone Richard M, Deangelo Daniel J, Galinsky Ilene, Estey Elihu, Lanza Carlo, Fox Edward, Ehninger Gerhard, Feldman Eric J, Schiller Gary J, Klimek Virginia M, Nimer Stephen D, Gilliland D Gary, Dutreix Catherine, Huntsman-Labed Alice, Virkus Jodi and Giles Francis J. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20101102.